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SHORT PAPER 
Drug-induced Parkinson’s disease 
modulates protein kinase A and Olfactory 
Marker Protein in the mouse olfactory bulb
Carla Mucignat1,2*  and Antonio Caretta2,3
Abstract 
Background: Olfaction is often affected in parkinsonian patients, but dopaminergic cells in the olfactory bulb are not 
affected by some Parkinson-inducing drugs. We investigated whether the drug MPTP produces the olfactory deficits 
typical of Parkinson and affects the olfactory bulb in mice.
Findings: Lesioned and control mice were tested for olfactory search, for motor and exploratory behavior. Brains and 
olfactory mucosa were investigated via immunohistochemistry for thyrosine hydroxylase, Olfactory Marker Protein 
and cyclic AMP-dependent protein kinase as an intracellular pathway involved in dopaminergic neurotransmission. 
MPTP induced motor impairment, but no deficit in olfactory search. Thyrosine hydroxylase did not differ in olfac-
tory bulb, while a strong decrease was detected in substantia nigra and tegmentum of MPTP mice. Olfactory Marker 
Protein decreased in the olfactory bulb of MPTP mice, while a cyclic AMP-dependent protein kinase increased in the 
inner granular layer of MPTP mice.
Conclusions: MPTP mice do not present behavioural deficits in olfactory search, yet immunoreactivity reveals 
modifications in the olfactory bulb, and suggests changes in intracellular signal processing, possibly linked to neuron 
survival after MPTP.
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Background
In human Parkinson’s disease (PD) patients, an impair-
ment in the sense of smell and in olfactory structures is 
often reported [1, 2]. Neurons of the olfactory system 
are affected by degenerative changes, like the presence of 
Lewy bodies [3, 4] at an early stage, when motor deficits 
are not yet apparent: hence, modifications of the olfac-
tory system can be used for early PD diagnosis [5].
Olfactory processing is linked to dopaminergic sign-
aling, which has a prominent role in the olfactory bulb 
(OB) circuitry: dopamine D2 receptors in terminals of 
olfactory neurons and in dendrites of mitral/tufted cells 
modulate glutamate release, and in terminals of GABAe-
rgic/dopaminergic cells they modulate GABA and 
dopamine release [6, 7]. Moreover, in olfactory neurons 
dopamine inhibits adenylyl cyclase [8] and in OB gran-
ule cells activation of D1 receptors modulates GABA A 
receptors through the cAMP/protein kinase A (PKA) 
activation [9].
Dopamine and cAMP signalling pathway mutu-
ally interact also in brain nuclei involved in PD. PKA 
stimulates dopamine uptake [10], and activates tyros-
ine hydroxylase (TH) [11]. On striatal GABAergic neu-
rons, D1 receptor activates PKA, that phosphorylates 
glutamate NMDA receptors [12]. PKA regulates dopa-
mine physiology and modulates the activity of proteins 
involved in PD, including LRRK2, alpha-synuclein, tau 
and TH [13–16].
The OB is one of the main dopaminergic nuclei in the 
brain [17]. It receives axons from new receptors that con-
tinuously differentiate in the olfactory neuroepithelium, 
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periglomerular and granular cells. Dopamine is a parac-
rine signal for differentiation of subventricular stem cells 
[18], therefore a deficit in dopaminergic cells acts also on 
neuron turnover in the OB [19]. Moreover, cAMP regu-
lates differentiation and survival of new neurons in the 
OB [20].
To better understand whether mesencephalic and OB 
dopaminergic neurons respond differentially to chemical 
insults, we investigated the changes in TH and PKA in the 




Experiments were authorized according to the directive 
86/609/EEC. Twelve C57BL/6j male mice 4  months old 
were used (Charles River, Lecco, Italy). MPTP hydrochlo-
ride (Sigma, Milan, Italy; 15 mg/kg in 0.9% NaCl, n = 6) 
or saline solution (0.9% NaCl, n  =  6) was i.p. injected, 
four times every 2 h.
Behavioral tests
Mice were weighted, evaluated for neurologic deficits 
and tested 5 days before and five after injections. On the 
day of injections, tests started 1 h after the last injection.
The open field test measures locomotion and 
exploration. The mouse was introduced in a cage 
(55 × 33 × 20 cm) for 10 min and videotaped. A software 
(Smart 2.5, 2B Biological Instruments, Varese, Italy) cal-
culated distance, resting time, and number of rearings on 
the walls [21]. Thigmotaxis was quantified by measuring 
the permanence time and the time spent resting in prox-
imity of the walls, excluding a central area (35 × 16 cm).
The pole test detects bradykinesia [22]: the mouse 
was placed on the top of a pole (1.5 cm diameter, 50 cm 
height). The time until it reached the floor was recorded 
(maximum 3 min).
The grip test [22] consisted in placing forepaws on the 
middle of a wire, 2 mm × 90 cm, 15 cm above the floor: 
the time to fall down or to reach the lateral platforms was 
recorded (maximum 3 min).
The cookie-finding test evaluates olfactory function 
[21]. On the second day pre-injection and after injection, 
mice were overnight deprived of food then put in a cage 
(42 ×  25 ×  15  cm) with a food pellet buried under the 
sawdust: the latency to discover it was recorded within 
5 min. The test was repeated after 1 h with a pellet in a 
visible position to control for motivation to eat. The test 
was not repeated every day in order to avoid unnecessary 
stress due to overnight food restriction.
The tests were repeated on all mice up to day 3 post-
injection, then half of the mice were sacrificed, on day 
4 and 5 three mice were tested in each group. The data 
collected before treatment were compared to those col-
lected after injection: data were analyzed with mixed 
design analysis of variance (ANOVA, factors Group: con-
trol/MPTP; Day: pre- vs. post-treatment) and post hoc 
Newman–Keuls, using Statistica 5 software (www.stat-
soft.com). The significant level was p  <  0.05. Data from 
behavioral tests are presented as mean ± SEM.
Immunohistochemistry
Three or 5  days after injection, mice were euthanized 
(Tanax 20  mg/kg, i.p.). After preincubation of paraffin-
embedded sections for 1 h with 2% bovine serum albu-
min, nose and brain sections were incubated overnight 
with Olfactory Marker Protein (OMP) antibody (Wako, 
Neuss, Germany, 1:600); brains were also incubated with 
TH (Santa Cruz Biotechnology, Heidelberg, Germany, 
1:100), or synaptophysin antibodies (Sigma, Milan, 
Italy, 1:100). Frozen sections were washed for 30  min 
in 2% Triton-X100, fixed for 1 min in formalin at 37  °C 
and incubated overnight with anti- murine PKA RIIal-
pha (Santa Cruz Biotechnology, Heidelberg, Germany, 
1:200); adjacent sections were incubated with 100  nM 
8-thioacetamido-fluorescein-cAMP (SAF-cAMP) to vis-
ualize PKA RI [23]. Secondary antibodies (Sigma, Milan, 
Italy; or Molecular Probes, Milan, Italy) 1:400 were incu-
bated 1 h at 37 °C. Slides were evaluated independently 
with a Leica microscope (objectives: 20×, 40×, 100×) 
by two observers on a semiquantitative 5-step scale. 
Unaltered images obtained using the same conditions 




Mice did not differ in body weight, before and after 
the treatment: before treatment, 25.1  ±  1.1 versus 
24.9 ± 1.1 g for controls and MPTP-treated, respectively; 
after treatment: 24.2 ±  1.1 versus 24.4 ±  1.2 g for con-
trols and MPTP-treated, respectively.
All mice during the first and second repetition of the 
tests improved their performance, to reach a steady-
state performance before the treatment (Fig.  1). After 
the treatment, MPTP-treated mice displayed some defi-
cits, in comparison to controls and to their pre-treatment 
scores.
The Cookie-finding test did not differ between controls 
and MPTP mice when food was hidden. Only the fac-
tor Day was significant, F(1,10) =  6.995, p  <  0.05: both 
groups after treatment were slower in retrieving hidden 
food, possibly as a consequence of the stress imposed by 
injections. MPTP mice did not display any obvious deficit 
with visible food. All mice were able to retrieve the food 
in both invisible and visible conditions.
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A reduction in motor activity after MPTP was appar-
ent in the open field, with a decrease in the distance 
travelled [Group: F(1,10)  =  20.094, p  <  0.005 controls: 
3136.9  ±  214.8  cm, MPTP: 1776.4  ±  214.3  cm] and 
in the number of rearings; the significant interaction 
Group × Day, F(1,10) = 7.817 p < 0.05, showed that only 
MPTP mice performed less rearings after the treatment, 
28.6 ± 5.4 and 36.8 ± 6.4 rearings for controls (p = 0.25), 
Fig. 1 Time course of behavioral performance in different tests. Control mice (times symbol) and MPTP mice (filled triangle) mean ± SEM were 
compared between groups on day 5 (last day before treatment) and day 6 (after treatment). The vertical line indicates the time of injections, asterisk 
indicates that both groups were different from the pre-treatment, hash symbol indicates that MPTP mice differ from controls after treatment.  
a Cookie-finding test, with the food pellet hidden. b Cookie-finding test with the food pellet in a visible position. c Open field test, distance 
travelled. d Number of rearings on the walls during the open field test. e Cumulative time spent resting in the open field test. f Time to reach the 
ground in the pole test. g Grip test, time to reach effectively the extremity. h Grip test, time to fall down
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and 21.8 ± 5.6 versus 3.0 ± 1.8 rearings in MPTP mice 
(p  <  0.005). The resting time differed between groups, 
F(1,10) = 22.834, p < 0.001, with MPTP mice resting for 
a longer time compared to controls, 550.0 ±  7.6 versus 
497.2 ± 7.9 s.
By analysing only to the zone adjacent to the walls, the 
factor Day was different, F(1,10) =  71.838, p  <  0.00001: 
both control and MPTP mice spent a longer time (includ-
ing walking and resting) along the walls after the treat-
ment, compared to the day before treatment (p < 0.005). 
This may be due to the stress of injections. Considering 
only the time spent resting in the proximity of the walls, 
both the factors and the interaction were significant. 
The interaction Group × Day, F(1,10) = 9.952 p < 0.02, 
showed that while controls did not vary (360.2  ±  16.3 
vs. 387.8  ±  17.5  s, respectively), MPTP mice spent a 
longer time resting along the border after the treatment 
(386.6 ± 16.9 vs. 522.5 ± 29.6 s before and after the treat-
ment respectively, p < 0.001).
In the pole test, the factor Day was significant, 
F(1,10) = 13.673, p < 0.005, and the interaction tended to 
significance, F(1,10) = 4.749, p = 0.054: only MPTP mice 
were slower in reaching the ground after the treatment 
(7.3 ± 2.7 vs. 62.1 ± 12.2 s), while controls did not vary 
significantly (11.8 ± 7.0 vs. 26.0 ± 9.0 s).
In the grip test, the time to reach one end was dif-
ferent: the significant interaction, F(1,10)  =  12.597 
p  <  0.01, showed that only MPTP mice took longer to 
reach the extremity after the treatment (24.1  ±  6.7 vs. 
156.6 ± 23.3 s in MPTP mice, p < 0.001, and in controls: 
25.5  ±  5.7 vs. 49.8  ±  20.5  s). Only mice treated with 
MPTP fell down (5 out of 6 mice), as shown by the inter-
action Group × Day, F(1,10) = 24.217, p < 0.001.
Immunohistochemistry
Data on immunohistochemistry are summarized in 
Table 1 and representative sections are shown in Fig. 2. As 
expected, TH was reduced in substantia nigra after MPTP 
(Fig. 2a, b), but did not change in the OB (Fig. 2c, d).
In the nose of both groups, OMP labelling was promi-
nent in olfactory neurons, olfactory fila, and vomerona-
sal neurons. However, the olfactory nerve and glomeruli 
in the main OB were consistently fainter in MPTP mice 
(Fig. 2e, f ). This difference was not present in the acces-
sory OB. Synaptophysin did not change in both control 
and MPTP mice.
No obvious modification was apparent in PKA RI, yet 
3  days after MPTP PKA RII was brighter in the inner 
granular layer of the main OB and in the granule cells of 
the accessory OB, compared to controls (Fig.  2g, h, see 
also [23]). Five days after MPTP, this difference was less 
apparent, the most intense granule cells were confined 
immediately below the mitral cell layer, while the inner 
granular layer was very faint.
Discussion
Multiple factors contribute to the onset and progress of PD, 
that initially targets few susceptible neuron types in motor 
nuclei of glossopharyngeal and vagus nerves, and in the 
anterior olfactory nucleus [2, 3, 24]. Many animal models 
are available for mimicking PD landmarks, however none 
can reproduce in full the human pathology. The picture is 
even more complicated by the presence of both motor and 
non-motor symptoms, whose assessment in animal models 
may be difficult and need careful overall interpretation (for 
a review, see [25]). We choose the MPTP model because 
we were interested in olfactory dysfunctions, which are a 
hallmark of early PD stages. MPTP administered acutely in 
mice can reproduce early stages of PD [26], however, it is 
not sufficient for fully exploring PD, since MPTP-injected 
mice recover spontaneously, which precludes the study of 
pharmacological interventions. Moreover, various strains 
of mice show different sensitivity to MPTP.
Table 1 OMP and TH immunostaining
No labeling (−); faint labeling (±); moderate labeling (+); intense labeling (++); 
very intense labeling (+++)
Control Day 3 Day 5
OMP
 Olfactory nerve +++ + +
 Olfactory glomeruli +++ + +
TH
 Olfactory bulb ++ ++ ++
 Substantia nigra +++ ± ±
(See figure on next page.) 
Fig. 2 Immunohistochemistry on horizontal brain sections. Bar 200 μm for a, b, e, f; 50 μm for c, d, g, h. a–d TH immunolabelling. a Substan-
tia nigra/ventral tegmental area appear labelled in a control mouse; caudal on the right. ip interpeduncular nucleus, sn substantia nigra, sum 
supramammillary nucleus, vta ventral tegmental area. b The same area is almost unlabelled in a MPTP mouse, 3 days after injections; rostral on 
the right. c, d Periglomerular cells are similarly labelled in a control mouse (c) and in a MPTP-treated mouse (d), 3 days after injections; caudal on 
top right. e, f OMP immunoreactivity in the olfactory bulb of a control (e) and a MPTP mouse (f), 3 days after injections. In the control mouse, the 
olfactory nerve and glomerular layer are labelled; also the accessory olfactory bulb glomerular layer is labelled. Caudal on the lower right. g, h RII 
immunoreactivity in the main olfactory bulb of a control (g) and a MPTP-treated mouse, 3 days after injections. Caudal on the top, lateral on the left. 
m mitral cell layer, ig inner granular layer
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PD implies a complex imbalance of the dopaminergic 
system. However, not all dopaminergic neurons in the 
brain are equally affected by degeneration.
Here, in MPTP mice olfactory search behavioural 
performance is normal, yet some modifications can be 
detected via immunoreactivity in the OB.
MPTP in mice induces both behavioral and neuro-
chemical changes that mimic human PD: altering free 
radicals quenching and reducing TH and dopamine 
transporter in the substantia nigra and striatum [27] 
result in motor impairments, bradykinesia and catalepsy 
[22]. However, MPTP does not worsen olfaction in both 
humans and mice [28, 29]. In our experiment, mice were 
impaired in motor performance, as shown by short trav-
elled distance and less rearings on the walls—an increase 
in the rearings is used as an index of anxiety. However, 
MPTP mice performed similarly to controls in olfac-
tory retrieving, which also included motor performance. 
This may be due to differential involvement of the moti-
vational system, which is conceivably more activated in 
discovering and reaching food items. PD patients are 
impaired in the motor but also in cognitive/integra-
tive levels of motor control [30], and often show apathy 
and indecisiveness [31]: similarly, our mice move under 
a sufficiently strong drive. However, their good perfor-
mance in the cookie-finding test does not imply a normal 
olfactory function. This test involves exposure to above-
threshold stimuli: it is possible that MPTP mice show 
subtler olfactory deficits. Noteworthy in a genetic PD 
model, mice were able to detect and habituate to odors, 
but showed deficits in more stringent olfactory tests [32].
MPTP modifies the expression of several proteins: 
in the striatum it reduces dopamine, TH, dopamine 
transporter, vesicle monoamine transporter and alpha-
synuclein, while monoaminooxidase A and B and cat-
echol-O-methyl-transferase remain unchanged [33]. 
Reduced TH levels were apparent in our MPTP mice in 
the brainstem dopaminergic nuclei.
The dopaminergic pathway is linked to cAMP intracel-
lular signalling in both brainstem and olfactory system: 
TH is induced by the cAMP-mediated signalling path-
way [34]. In PD substantia nigra, both D1 receptors and 
DARPP32 appear downregulated [35]. Dopaminergic 
neurons are protected against MPTP toxicity after the 
inhibition of monoaminooxydase-B, which acts via PKA 
[36]. Moreover, substantia nigra is protected from MPTP 
by phosphodiesterase inhibitors, that enhance cAMP 
and subsequently PKA [37]. Here, the transient increase 
in OB PKA after MPTP may be linked to a protective 
response in these neurons, opening a new challenge for 
neuroprotection in other brain areas.
PKA participates also in reaction to MPTP, so that in 
lesioned mice activation of PKA with forskolin induces 
an exaggerated increase in TH [38]. Moreover, glu-
tamatergic corticostriatal pathway is overactive after 
nigrostriatal denervation, and subsequently striatal PKA-
dependent NMDA phosphorylation increases [39].
Striatal deafferentation increases neurogenesis in the 
olfactory bulb, mostly for new dopaminergic cells [40, 
41]. In our MPTP mice, the PKA transient increase in 
OB inner granular layer, which hosts also the developing 
new neurons coming from the subventricular zone, sug-
gests an upregulation of the cAMP-mediated signalling 
in response to MPTP, which should be studied in greater 
detail.
The differential effects of MPTP in OB neurons were 
related to the lack of the dopamine transporter, which 
uptakes the toxic MPTP metabolite, making OB neu-
rons MPTP-resistant [42]. While further studies, includ-
ing other animal PD models like 6-OHDA, are needed, 
the present data confirm that TH immunoreactivity is 
not affected in the OB after MPTP injection. However, 
we challenge the idea that the olfactory system is not 
affected by MPTP at all, since a decrease in OMP and a 
transient increase in PKA RII were consistently observed, 
suggesting a specific response to MPTP in OB neurons, 
that is not apparent in the nigra, and could be exploited 
for therapeutic purposes.
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